Free tool
FAERS Monitor: Combogesic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209471 or its brand name (Combogesic, Acetaminophen, Ibuprofen). Reports on generic versions are filed under their own applications.
Reports
219
Serious
18
8% of reports
Hospitalization
7
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective47
- drug effective for unapproved indication30
- therapeutic product effect incomplete27
- drug effect less than expected15
- underdose13
- overdose10
- incorrect dose administered9
- drug ineffective for unapproved indication8
- hypersensitivity8
- off label use7
- inappropriate schedule of product administration6
- drug hypersensitivity5
- malaise4
- somnolence4
- diarrhoea3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2023 | 108 |
| 2024 | 55 |
| 2025 | 43 |
| 2026 | 12 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,940 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug effective for unapproved indicationSignal | 30 | 98.5 | 70.6 | 2,799 |
| drug effect less than expectedSignal | 15 | 97.3 | 59.7 | 1,335 |
| therapeutic product effect incompleteSignal | 27 | 36.5 | 25.6 | 899 |
| underdoseSignal | 13 | 17.1 | 10.1 | 182 |
| drug ineffective for unapproved indicationSignal | 8 | 14.0 | 7.1 | 84 |
| overdoseSignal | 10 | 4.5 | 2.4 | 24 |
| hypersensitivitySignal | 8 | 4.1 | 2.1 | 16 |
| incorrect dose administeredSignal | 9 | 3.8 | 2.0 | 16 |
| drug ineffectiveSignal | 47 | 3.4 | 2.7 | 84 |
| inappropriate schedule of product administrationSignal | 6 | 3.2 | 1.5 | 7 |
| drug hypersensitivity | 5 | 2.5 | 1.0 | 3 |
| somnolence | 4 | 1.9 | 0.7 | 1 |
| malaise | 4 | 0.9 | 0.3 | 0 |
| off label use | 7 | 0.8 | 0.4 | 0 |
| diarrhoea | 3 | 0.4 | 0.1 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.